Trial reportUpdates in surgery2026
Effects of stoma discharge reinfusion on low anterior resection syndrome and the gut microbiota following sphincter-preserving surgery for middle and low rectal cancer: a randomized clinical trial.
Trial report in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05461248 (An Exploratory Study on the Recovery of Intestinal Flora and Intestinal Function by Preventing Stoma Discharge Reinfusion After Sphincter Preservation for Middle and Low Rectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory Study on the Recovery of Intestinal Flora and Intestinal Function by Preventing Stoma Discharge Reinfusion After Sphincter Preservation for Middle and Low Rectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low anterior resection syndrome (LARS) is a disorder of bowel function that develops after sphincter-preserving surgery for rectal cancer. Transanal irrigation is a treatment for low anterior resection syndrome. This is a single-center prospective randomized controlled trial comparing stoma discharge reinfusion versus standard care 1 month following sphincter-preserving and temporary loop ileostomy surgery was performed. The primary endpoint was the proportion of patients with major LARS at 6 months after ileostomy reversal. Secondary endpoints included Glazer pelvic floor muscle (PFM) surface electromyography (SEMG) and microbiota analysis at 1 month after ileostomy reversal and Quality-of-Life Questionnaire Core 30 (QLQ C30) analysis during follow-up period. Of 60 randomized patients, 52 were included in the analysis (reinfusion group, n = 28; standard care group n = 24). The proportion of patients with major LARS was statistically lower after stoma discharge reinfusion compared with standard care at 6 months after ileostomy reversal (10.7% vs 41.7%, p = 0.01). Glazer PFM SEMG values were significantly higher 1 week prior to ileostomy reversal: phasic contractions (p = 0.04), tonic contractions (p = 0.02), and endurance contractions (p = 0.002); but there were no significant differences at 1 month after ileostomy reversal. QLQ C30 questionnaire showed higher functional scores, but symptom scores and global health status did not improve. Microbiota analysis revealed no significant differences in either beta or alpha diversity. Nevertheless, differentially abundant species were identified between LARS and no-LARS groups. Stoma discharge reinfusion reduced LARS severity and improved anal function and microbiota dysbiosis in patients who underwent sphincter-preserving surgery.Registration number and date of registration NCT05461248, 2022-07-14 ( http://www.clinicaltrials.gov ).
Indexed as
Identifiers
41233674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.